- Home
- SNTI vs NXN Comparison
SNTI vs NXN Comparison
Compare SNTI & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- NXN
- Stock Information
- Founded
- SNTI 2016
- NXN 1992
- Country
- SNTI United States
- NXN United States
- Employees
- SNTI N/A
- NXN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- NXN Trusts Except Educational Religious and Charitable
- Sector
- SNTI Health Care
- NXN Finance
- Exchange
- SNTI Nasdaq
- NXN Nasdaq
- Market Cap
- SNTI 39.6M
- NXN 45.4M
- IPO Year
- SNTI N/A
- NXN N/A
- Fundamental
- Price
- SNTI $1.56
- NXN $11.67
- Analyst Decision
- SNTI Strong Buy
- NXN
- Analyst Count
- SNTI 2
- NXN 0
- Target Price
- SNTI $8.50
- NXN N/A
- AVG Volume (30 Days)
- SNTI 107.2K
- NXN 9.7K
- Earning Date
- SNTI 08-07-2025
- NXN 01-01-0001
- Dividend Yield
- SNTI N/A
- NXN 4.23%
- EPS Growth
- SNTI N/A
- NXN N/A
- EPS
- SNTI N/A
- NXN 0.24
- Revenue
- SNTI N/A
- NXN N/A
- Revenue This Year
- SNTI N/A
- NXN N/A
- Revenue Next Year
- SNTI $150.00
- NXN N/A
- P/E Ratio
- SNTI N/A
- NXN $48.42
- Revenue Growth
- SNTI N/A
- NXN N/A
- 52 Week Low
- SNTI $1.46
- NXN $10.64
- 52 Week High
- SNTI $16.94
- NXN $12.45
- Technical
- Relative Strength Index (RSI)
- SNTI 37.24
- NXN 54.93
- Support Level
- SNTI $1.52
- NXN $11.60
- Resistance Level
- SNTI $1.65
- NXN $11.78
- Average True Range (ATR)
- SNTI 0.10
- NXN 0.08
- MACD
- SNTI 0.03
- NXN 0.00
- Stochastic Oscillator
- SNTI 50.00
- NXN 59.26
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.